Background/Objectives: Seasonal influenza, pneumococcal disease, and COVID-19 pose major public health challenges, particularly for individuals with chronic illnesses. This study examined vaccination coverage for influenza, pneumococcal disease, and SARS-CoV-2 among patients with chronic liver disease and cirrhosis and explored the sociodemographic and clinical factors influencing it. Methods: A cross-sectional study, conducted from March 2022 to July 2023 at two university hepatology outpatient clinics in Athens, Greece. The study population consisted of patients with a diagnosis of chronic liver disease (hepatocellular carcinoma and hepatitis) and liver cirrhosis. Results: A convenience sample size of 300 patients (age ≥ 30) participated. Regarding their vaccination, 88.3% were vaccinated against SAR-COVID-19, 44.8% against pneumococcus, and 54.7% against seasonal influenza this year. Patients’ belief that annual vaccination is the best method for influenza prevention was found to be significantly higher among older patients and those with comorbidities. Additionally, patients who had been vaccinated against seasonal influenza (this year or every year), against pneumococcus, or SARS-CoV-2 agreed significantly that annual vaccination is the best method for influenza prevention. In addition, patients who were informed about vaccination by their doctor/nurse agreed significantly more with that. Multiple logistic regression found that a four times greater probability of being fully vaccinated according to the national vaccination program was found in patients who were informed about vaccination by a doctor/nurse. Moreover, as patients’ age increased, so did the probability of being fully vaccinated. Conclusions: The study’s findings are significant and can be utilized within national public health initiatives and by healthcare professionals during patient interactions, ensuring that younger patients and those apprehensive about vaccine efficacy and safety receive focused attention to facilitate adherence to annual vaccinations and all vaccines included in national programs.
Background/Objectives: Seasonal influenza, pneumococcal disease, and Corona-virus disease (COVID-19) constitute a serious public health concern, as they impact a substantial portion of the population, in particular patients with chronic diseases. The aim of this study was to investigate vaccine coverage in patients with chronic liver disease and cirrhosis, about influenza, pneumococcal, and COVID-19 vaccines, and to identify the sociodemographic and clinical factors affecting it. Methods: Α cross-sectional study was conducted. The study population consisted of patients with a diagnosis of chronic liver disease and liver cirrhosis. The study was conducted from March 2022 to July 2023. Results: A convenience sample size of 300 patients (age 30) participated. Regarding their vaccination, 88.3% were vaccinated against SAR-Covid-19, 44.8% against pneumococcus, and 54.7% against seasonal influenza this year. Patients’ belief that annual vaccination is the best method for influenza prevention was found to be significantly higher among older patients and those with comorbidities. Also, pa-tients who had been vaccinated against seasonal influenza (this year or every year), against pneumococcus, or SAR-Covid-19 agreed significantly that annual vaccination is the best method for influenza prevention. In addition, patients who were informed about vaccination by their doctor/ nurse agreed significantly more with that. Multiple logistic regression found that a four times greater probability of being fully vaccinated according to the national vaccination program was found in patients who were in-formed about vaccination by a doctor/nurse. Moreover, as patients’ age increased, so did the probability of being fully vaccinated. Conclusions: The study's findings can be uti-lized in public health initiatives and by healthcare practitioners addressing patients with low vaccination adherence.
Vaccination rates remain low despite the influenza vaccine’s proven safety and efficacy in protecting vulnerable groups, such as individuals diagnosed with liver disease. This cross-sectional study investigated influenza vaccination coverage, attitudes, beliefs, and influencing factors among 152 patients with liver disease in Greece. Over half (53.6%) were diagnosed with hepatitis, and 40.4% with cirrhosis. Overall, 58.6% of participants received the seasonal influenza vaccine. Multivariate logistic regression showed that older age (OR = 1.07, 95% CI: 1.02–1.11, p = .002), prior pneumococcal vaccination (OR = 17.98, 95% CI: 6.66–48.52, p < .001), and COVID-19 vaccination (OR = 5.77, 95% CI: 1.17–28.46, p = .031) were significantly associated with influenza vaccination in the current season. Similarly, older age (OR = 1.09, 95% CI: 1.04–1.14, p < .001) and pneumococcal vaccination (OR = 25.75, 95% CI: 9.20–72.05, p < .001) were linked to annual influenza vaccination. About half of the participants are vaccinated yearly. These findings highlight the need for targeted public health strategies to improve vaccination rates among patients with liver disease. Gastroenterology healthcare professionals, as trusted information sources, can play a key role in promoting vaccine uptake and improving immunization coverage in this high-risk population.